Targeting Hsp90: small-molecule inhibitors and their clinical development
Top Cited Papers
- 31 July 2008
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 8 (4) , 370-374
- https://doi.org/10.1016/j.coph.2008.06.015
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and MetastasisCancer Research, 2008
- BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitorsMolecular Cancer Therapeutics, 2008
- Development and application of Hsp90 inhibitorsDrug Discovery Today, 2008
- Discovery and development of purine-scaffold Hsp90 inhibitorsExpert Opinion on Drug Discovery, 2007
- Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancerNature Chemical Biology, 2007
- Heat shock protein 90: The cancer chaperoneJournal of Biosciences, 2007
- Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.2006
- ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemiaBlood, 2005
- HSP90 and the chaperoning of cancerNature Reviews Cancer, 2005
- Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to GeldanamycinsCancer Research, 2005